PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34599023-1	2021	BACKGROUND: Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic antitumor activity in combination with anti-programmed death-1/ligand-1 agents.	sitravatinib	12-24	TYRO3 protein tyrosine kinase	Homo sapiens	67-72
34599023-1	2021	BACKGROUND: Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic antitumor activity in combination with anti-programmed death-1/ligand-1 agents.	sitravatinib	12-24	AXL receptor tyrosine kinase	Homo sapiens	74-77
34599023-1	2021	BACKGROUND: Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase the M1 to M2-polarized tumor-associated macrophages ratio in the tumor microenvironment and have synergistic antitumor activity in combination with anti-programmed death-1/ligand-1 agents.	sitravatinib	12-24	MER proto-oncogene, tyrosine kinase	Homo sapiens	79-84
32525624-0	2020	Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor.	sitravatinib	75-87	ATP binding cassette subfamily B member 1	Homo sapiens	27-32
32525624-2	2020	In this work, we evaluated the sensitizing effect of sitravatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), on ATP-binding cassette subfamily B member 1 (ABCB1)- and ATP-binding cassette subfamily C member 10 (ABCC10)-mediated MDR.	sitravatinib	53-65	ATP binding cassette subfamily B member 1	Homo sapiens	120-161
32525624-2	2020	In this work, we evaluated the sensitizing effect of sitravatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), on ATP-binding cassette subfamily B member 1 (ABCB1)- and ATP-binding cassette subfamily C member 10 (ABCC10)-mediated MDR.	sitravatinib	53-65	ATP binding cassette subfamily B member 1	Homo sapiens	163-168
32525624-2	2020	In this work, we evaluated the sensitizing effect of sitravatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), on ATP-binding cassette subfamily B member 1 (ABCB1)- and ATP-binding cassette subfamily C member 10 (ABCC10)-mediated MDR.	sitravatinib	53-65	ATP binding cassette subfamily C member 10	Homo sapiens	175-217
32525624-2	2020	In this work, we evaluated the sensitizing effect of sitravatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), on ATP-binding cassette subfamily B member 1 (ABCB1)- and ATP-binding cassette subfamily C member 10 (ABCC10)-mediated MDR.	sitravatinib	53-65	ATP binding cassette subfamily C member 10	Homo sapiens	219-225
32525624-6	2020	RESULTS: Sitravatinib considerably reversed MDR mediated by ABCB1 and partially antagonized ABCC10-mediated MDR.	sitravatinib	9-21	ATP binding cassette subfamily B member 1	Homo sapiens	60-65
32525624-6	2020	RESULTS: Sitravatinib considerably reversed MDR mediated by ABCB1 and partially antagonized ABCC10-mediated MDR.	sitravatinib	9-21	ATP binding cassette subfamily C member 10	Homo sapiens	92-98
32525624-7	2020	Our in silico docking simulation analysis indicated that sitravatinib strongly and stably bound to the transmembrane domain of ABCB1 human-mouse chimeric model.	sitravatinib	57-69	ATP binding cassette subfamily B member 1	Homo sapiens	127-132
32525624-8	2020	Furthermore, sitravatinib inhibited hydrolysis of ATP and synchronously decreased the efflux function of ABCB1.	sitravatinib	13-25	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	105-110
32525624-11	2020	More importantly, sitravatinib could remarkably restore the antitumor activity of vincristine in ABCB1-mediated xenograft model without observable toxic effect.	sitravatinib	18-30	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	97-102
31941029-0	2020	Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.	sitravatinib	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	24-29
32477943-0	2020	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro.	sitravatinib	0-12	TXK tyrosine kinase	Homo sapiens	16-31
32477943-0	2020	Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro.	sitravatinib	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-83
32477943-1	2020	Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation.	sitravatinib	0-12	TXK tyrosine kinase	Homo sapiens	65-80
32477943-1	2020	Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation.	sitravatinib	26-33	TXK tyrosine kinase	Homo sapiens	65-80
32477943-1	2020	Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical evaluation.	sitravatinib	37-43	TXK tyrosine kinase	Homo sapiens	65-80
32477943-2	2020	Herein, we explored the activity of sitravatinib toward multidrug resistance (MDR) by emphasizing its inhibitory effect on ATP-binding cassette super-family G member 2 (ABCG2).	sitravatinib	36-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	123-167
32477943-2	2020	Herein, we explored the activity of sitravatinib toward multidrug resistance (MDR) by emphasizing its inhibitory effect on ATP-binding cassette super-family G member 2 (ABCG2).	sitravatinib	36-48	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	169-174
32477943-5	2020	Also, an MTT assay indicated that sitravatinib at 3 muM had the ability to restore the antineoplastic effect of various ABCG2 substrates in both drug-selected and gene-transfected ABCG2-overexpressing cell lines.	sitravatinib	34-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	120-125
32477943-5	2020	Also, an MTT assay indicated that sitravatinib at 3 muM had the ability to restore the antineoplastic effect of various ABCG2 substrates in both drug-selected and gene-transfected ABCG2-overexpressing cell lines.	sitravatinib	34-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	180-185
32477943-6	2020	In further tritium-labeled mitoxantrone transportation study, sitravatinib at 3 muM blocked the efflux function mediated by ABCG2 and as a result, increased the intracellular concentration of anticancer drugs.	sitravatinib	62-74	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	124-129
32477943-8	2020	An ATPase assay demonstrated that ATPase activity of ABCG2 was inhibited in a concentration-dependent manner with sitravatinib; thus, the energy source to pump out compounds was interfered.	sitravatinib	114-126	dynein axonemal heavy chain 8	Homo sapiens	3-9
32477943-8	2020	An ATPase assay demonstrated that ATPase activity of ABCG2 was inhibited in a concentration-dependent manner with sitravatinib; thus, the energy source to pump out compounds was interfered.	sitravatinib	114-126	dynein axonemal heavy chain 8	Homo sapiens	34-40
32477943-8	2020	An ATPase assay demonstrated that ATPase activity of ABCG2 was inhibited in a concentration-dependent manner with sitravatinib; thus, the energy source to pump out compounds was interfered.	sitravatinib	114-126	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	53-58
32477943-9	2020	Collectively, the results of this study open new avenues for sitravatinib working as an ABCG2 inhibitor which restores the antineoplastic activity of anticancer drugs known to be ABCG2 substrates.	sitravatinib	61-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	88-93
32477943-9	2020	Collectively, the results of this study open new avenues for sitravatinib working as an ABCG2 inhibitor which restores the antineoplastic activity of anticancer drugs known to be ABCG2 substrates.	sitravatinib	61-73	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	179-184
31941029-5	2020	We discovered that at submicromolar concentrations, sitravatinib re-sensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.	sitravatinib	52-64	ATP binding cassette subfamily B member 1	Homo sapiens	79-84
31941029-5	2020	We discovered that at submicromolar concentrations, sitravatinib re-sensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.	sitravatinib	52-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	90-95
31941029-6	2020	We found that sitravatinib blocks the drug efflux function of ABCB1 and ABCG2 in a concentration-dependent manner but does not significantly alter the protein expression of ABCB1 or ABCG2 in multidrug-resistant cancer cells.	sitravatinib	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	62-67
31941029-6	2020	We found that sitravatinib blocks the drug efflux function of ABCB1 and ABCG2 in a concentration-dependent manner but does not significantly alter the protein expression of ABCB1 or ABCG2 in multidrug-resistant cancer cells.	sitravatinib	14-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	72-77
31941029-7	2020	In conclusion, we reveal a potential drug repositioning treatment option for multidrug-resistant cancers by targeting ABCB1 and ABCG2 with sitravatinib and should be further investigated in future clinical trials.	sitravatinib	139-151	ATP binding cassette subfamily B member 1	Homo sapiens	118-123
31941029-7	2020	In conclusion, we reveal a potential drug repositioning treatment option for multidrug-resistant cancers by targeting ABCB1 and ABCG2 with sitravatinib and should be further investigated in future clinical trials.	sitravatinib	139-151	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	128-133
31941029-0	2020	Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.	sitravatinib	0-12	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	35-40
31941029-4	2020	In the present study, we investigated the effect of sitravatinib, a novel multitargeted receptor tyrosine kinase inhibitor, on human ABCB1 and ABCG2 in multidrug-resistant cancer cell lines.	sitravatinib	52-64	ATP binding cassette subfamily B member 1	Homo sapiens	133-138
31941029-4	2020	In the present study, we investigated the effect of sitravatinib, a novel multitargeted receptor tyrosine kinase inhibitor, on human ABCB1 and ABCG2 in multidrug-resistant cancer cell lines.	sitravatinib	52-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	143-148
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	17-29	Myeloproliferative syndrome, transient (transient abnormal myelopoiesis)	Homo sapiens	85-88
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	17-29	TYRO3 protein tyrosine kinase	Homo sapiens	90-95
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	17-29	AXL receptor tyrosine kinase	Homo sapiens	97-100
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	17-29	MER proto-oncogene, tyrosine kinase	Homo sapiens	102-107
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	31-38	Myeloproliferative syndrome, transient (transient abnormal myelopoiesis)	Homo sapiens	85-88
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	31-38	TYRO3 protein tyrosine kinase	Homo sapiens	90-95
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	31-38	AXL receptor tyrosine kinase	Homo sapiens	97-100
31369645-3	2019	Here we examined sitravatinib (MGCD516), a spectrum-selective TKI able to block MET, TAM (TYRO3, AXL, MerTK) and multiple receptor families (including PDGFRs, VEGFRs, and Ephs).	sitravatinib	31-38	MER proto-oncogene, tyrosine kinase	Homo sapiens	102-107
30385724-3	2018	Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment.	sitravatinib	0-12	TYRO3 protein tyrosine kinase	Homo sapiens	78-83
30385724-3	2018	Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment.	sitravatinib	0-12	AXL receptor tyrosine kinase	Homo sapiens	85-88
30385724-3	2018	Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment.	sitravatinib	0-12	MER proto-oncogene, tyrosine kinase	Homo sapiens	90-95
30385724-3	2018	Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment.	sitravatinib	0-12	kinase insert domain receptor	Homo sapiens	152-157
30385724-3	2018	Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment.	sitravatinib	0-12	platelet derived growth factor receptor beta	Homo sapiens	162-167
30385724-3	2018	Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment.	sitravatinib	0-12	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	181-184
30385724-3	2018	Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domain-containing receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment.	sitravatinib	0-12	ret proto-oncogene	Homo sapiens	191-194